Literature DB >> 29064485

Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials.

C Piette1, S Suciu2, E Clappier3,4, Y Bertrand5, S Drunat3, S Girard6, K Yakouben7, G Plat8, N Dastugue8, F Mazingue9, N Grardel9, N van Roy10, A Uyttebroeck11, V Costa12, O Minckes13, N Sirvent14, P Simon15, P Lutz16, A Ferster17, C Pluchart18, M Poirée19, C Freycon20, M-F Dresse1, F Millot21, C Chantrain22, J van der Werff Ten Bosch23, K Norga24, C Gilotay2, P-S Rohrlich19, Y Benoit25, H Cavé3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29064485     DOI： 10.1038/leu.2017.289

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  TEL-AML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemia.

Authors:  S Avigad; G Kuperstein; J Zilberstein; E Liberzon; B Stark; I Gelernter; Y Kodman; D Luria; S Ash; J Stein; Y Goshen; I Yaniv; I J Cohen; R Zaizov
Journal:  Leukemia       Date:  1999-03       Impact factor: 11.528

2.  ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.

Authors:  D Bhojwani; D Pei; J T Sandlund; S Jeha; R C Ribeiro; J E Rubnitz; S C Raimondi; S Shurtleff; M Onciu; C Cheng; E Coustan-Smith; W P Bowman; S C Howard; M L Metzger; H Inaba; W Leung; W E Evans; D Campana; M V Relling; C-H Pui
Journal:  Leukemia       Date:  2011-08-26       Impact factor: 11.528

3.  Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group.

Authors:  E Vilmer; S Suciu; A Ferster; Y Bertrand; H Cavé; A Thyss; Y Benoit; N Dastugue; M Fournier; G Souillet; A M Manel; A Robert; B Nelken; F Millot; P Lutz; X Rialland; F Mechinaud; P Boutard; C Behar; J M Chantraine; E Plouvier; G Laureys; P Brock; A Uyttebroeck; G Margueritte; D Plantaz; L Norton; N Francotte; J Gyselinck; C Waterkeyn; G Solbu; N Philippe; J Otten
Journal:  Leukemia       Date:  2000-12       Impact factor: 11.528

4.  Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.

Authors:  Michel Duval; Stefan Suciu; Alina Ferster; Xavier Rialland; Brigitte Nelken; Patrick Lutz; Yves Benoit; Alain Robert; Anne-Marie Manel; Etienne Vilmer; Jacques Otten; Noël Philippe
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

5.  Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG.

Authors:  J van der Werff Ten Bosch; S Suciu; A Thyss; Y Bertrand; L Norton; F Mazingue; A Uyttebroeck; P Lutz; A Robert; P Boutard; A Ferster; E Plouvier; P Maes; M Munzer; D Plantaz; M-F Dresse; P Philippet; N Sirvent; C Waterkeyn; E Vilmer; N Philippe; J Otten
Journal:  Leukemia       Date:  2005-05       Impact factor: 11.528

6.  Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis.

Authors:  Gianluigi Zaza; Wenjian Yang; Leo Kager; Meyling Cheok; James Downing; Ching-Hon Pui; Cheng Cheng; Mary V Relling; William E Evans
Journal:  Blood       Date:  2004-05-13       Impact factor: 22.113

7.  Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01.

Authors:  Mignon L Loh; Meredith A Goldwasser; Lewis B Silverman; Wing-Man Poon; Shashaank Vattikuti; Angelo Cardoso; Donna S Neuberg; Kevin M Shannon; Stephen E Sallan; D Gary Gilliland
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

8.  Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial.

Authors:  Carine Domenech; Stefan Suciu; Barbara De Moerloose; Françoise Mazingue; Geneviève Plat; Alina Ferster; Anne Uyttebroeck; Nicolas Sirvent; Patrick Lutz; Karima Yakouben; Martine Munzer; Pierre Röhrlich; Dominique Plantaz; Frederic Millot; Pierre Philippet; Nicole Dastugue; Sandrine Girard; Hélène Cavé; Yves Benoit; Yves Bertrandfor
Journal:  Haematologica       Date:  2014-04-11       Impact factor: 9.941

9.  Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia.

Authors:  E Masson; T W Synold; M V Relling; J D Schuetz; J T Sandlund; C H Pui; W E Evans
Journal:  Leukemia       Date:  1996-01       Impact factor: 11.528

10.  Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.

Authors:  Anja Möricke; Martin Zimmermann; Maria Grazia Valsecchi; Martin Stanulla; Andrea Biondi; Georg Mann; Franco Locatelli; Giovanni Cazzaniga; Felix Niggli; Maurizio Aricò; Claus R Bartram; Andishe Attarbaschi; Daniela Silvestri; Rita Beier; Giuseppe Basso; Richard Ratei; Andreas E Kulozik; Luca Lo Nigro; Bernhard Kremens; Jeanette Greiner; Rosanna Parasole; Jochen Harbott; Roberta Caruso; Arend von Stackelberg; Elena Barisone; Claudia Rössig; Valentino Conter; Martin Schrappe
Journal:  Blood       Date:  2016-02-17       Impact factor: 22.113
View more
  4 in total

1.  Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.

Authors:  Ikuya Usami; Toshihiko Imamura; Yoshihiro Takahashi; So-Ichi Suenobu; Daiichiro Hasegawa; Yoshiko Hashii; Takao Deguchi; Tsukasa Hori; Akira Shimada; Koji Kato; Eturou Ito; Akiko Moriya-Saito; Hirohide Kawasaki; Hiroki Hori; Keiko Yumura-Yagi; Junichi Hara; Atsushi Sato; Keizo Horibe
Journal:  Int J Hematol       Date:  2019-01-28       Impact factor: 2.490

Review 2.  Fusion-associated carcinomas of the breast: Diagnostic, prognostic, and therapeutic significance.

Authors:  Suet Kee Loo; Megan E Yates; Sichun Yang; Steffi Oesterreich; Adrian V Lee; Xiao-Song Wang
Journal:  Genes Chromosomes Cancer       Date:  2022-02-17       Impact factor: 5.006

3.  [Clinical features and prognosis of ETV6-RUNX1-positive childhood B-precursor acute lymphocyte leukemia].

Authors:  Y Z Zheng; L L Pan; J Li; Z S Chen; X L Hua; S H Le; H Zheng; C Chen; J D Hu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-01-14

4.  Prognostic Value and Outcome for ETV6/RUNX1-Positive Pediatric Acute Lymphoblastic Leukemia: A Report From the South China Children's Leukemia Group.

Authors:  Kun-Yin Qiu; Hong-Gui Xu; Xue-Qun Luo; Hui-Rong Mai; Ning Liao; Li-Hua Yang; Min-Cui Zheng; Wu-Qing Wan; Xue-Dong Wu; Ri-Yang Liu; Qi-Wen Chen; Hui-Qin Chen; Xiao-Fei Sun; Hua Jiang; Xing-Jiang Long; Guo-Hua Chen; Xin-Yu Li; Chang-Gang Li; Li-Bin Huang; Ya-Yun Ling; Dan-Na Lin; Chuan Wen; Wen-Yong Kuang; Xiao-Qin Feng; Zhong-Lv Ye; Bei-Yan Wu; Xiang-Lin He; Qiao-Ru Li; Li-Na Wang; Xian-Ling Kong; Lu-Hong Xu; Chi-Kong Li; Jian-Pei Fang
Journal:  Front Oncol       Date:  2021-12-20       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.